Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doc328
Boehringer and Walgreens partner to enhance clinical trial accessibility
May 3, 2024
The deal will aid in using select Walgreens pharmacies as clinical trial sites for individuals with obesity, overweight, and type 2 diabetes. Credit:
Boehringer Ingelheim and US-based pharmacy store chain Walgreens have entered into a strategic partnership to optimize clinical trial recruitment and improve accessibility, inclusivity and equity.
This deal expects to use select Walgreens pharmacies as clinical trial sites for individuals with obesity, overweight, and type 2 diabetes, focusing on Phase III clinical research.
The initiative targets the dismantling of barriers to clinical trial participation, aiming to achieve equitable health representation, particularly among Black and Hispanic communities in the US.
These groups are claimed to have historically been facing underrepresentation in clinical trials and are more likely to be affected by obesity.
https://www.clinicaltrialsarena.com/news/boehringer-walgreens-trial-accessibility/
Mari Tide is proposed to be dosed monthly which might be very beneficial as far as side effects.
We'll see
In the not-too-distant future, automatic emergency braking will have to come standard on all new passenger vehicles in the US, a requirement that the government says will save hundreds of lives and prevent thousands of injuries every year.
The National Highway Traffic Safety Administration unveiled the final version of the new regulation on Monday and called it the most significant safety rule in the past two decades.
It’s designed to prevent many rear-end and pedestrian collisions and reduce the roughly 40,000 traffic deaths that happen each year.
The new rules are designed to prevent many rear-end and pedestrian collisions and reduce the roughly 40,000 traffic deaths that happen each year.
“We’re living through a crisis in roadway deaths,” Transportation Secretary Pete Buttigieg said in an interview. “So we need to do something about it.”
It’s the government’s first attempt to regulate automated driving functions and is likely to help curb some of the problems that have surfaced with driver-assist and fully automated driving systems.
Although about 90% of new vehicles have the automatic braking standard now under a voluntary agreement with automakers, at present there are no performance requirements, so some systems are may not be that effective.
The new regulations set standards for vehicles to automatically stop and avoid hitting other vehicles or pedestrians, even at night.
“Part of how I think we’re going to turn the corner on the unacceptable level of roadway deaths that we just lived with for my entire lifetime is through these kinds of technologies,” said Buttigieg, who is 42. “We need to make sure we set high performance standards.”
The regulation, which will require additional engineering to bolster software and possibly add hardware such as radar, won’t go into effect for more than five years.
That will give automakers time to bolster their systems during the normal model update cycle, NHTSA said.
It also will drive up prices, which NHTSA estimates at $354 million per year in 2020 dollars, or $82 per vehicle. But Buttigieg said it will save 362 lives per year, prevent about 24,000 injuries and save billions in property damage.
Doesn't anyone at NHTSA know how to use a calculator. There's around 13-14 million new cars sold every year. That's north of a billion.
I'm sure the worry is about buying stock using borrowed funds. I think they paid a average of $18.79 plus the added tax penalty and now will pay XX percent on the debt they incurred.
It's like buying stock on margin except they'll never get a call.
This Steel Maker’s Stock Buyback Backfired. How Not to Get Burned.
By Al Root
April 25, 2024, 2:30 am EDT
Cleveland-Cliffs spent some $600 million repurchasing 30.4 million shares in the first quarter, amounting to about 6% of the total stock outstanding.
CLF reported first-quarter earnings on Monday. Bottom-line earnings missed estimates by a few cents a share, and the stock dropped 11%. That wasn’t the biggest reason for the drop, though.
The company spent some $600 million repurchasing 30.4 million shares in the first quarter, amounting to about 6% of the total stock outstanding. It also announced an additional $1.5 billion repurchase authorization. It had stopped paying a quarterly dividend during the pandemic.
Investors typically cheer large capital returns, whether they be buybacks or dividends. The problem is that Wall Street projects a 2024 free cash flow for the company of about $530 million, and $770 million for 2025—and those numbers don’t support its buybacks.
Capital return to shareholders is great, but investors don’t like robbing Peter to pay Paul.
https://www.barrons.com/articles/3m-cleveland-cliffs-buyback-dividends-c646c1d3?mod=hp_LEAD_6
typo
$790to $810
USW compares tentative Cleveland Cliffs agreement with current US Steel proposal
With two days remaining before the expiration on Thursday, Sept. 1, of the United Steelworkers’
master contract with Cleveland-Cliffs and U.S. Steel Corporation, USW is comparing the
tentative agreement announced by Cliffs over the weekend with U.S. Steel’s current proposal.
According to a statement released today, Tuesday, Aug. 30:
LENGTH OF CONTRACT
CLIFFS: Four years.
USS: Four years.
WAGES
*CLIFFS: 8 percent raise in 2022; then 4 percent, 4 percent, and 4 percent.
*USW: 3 percent raise in 2022; then 2.5 percent, 2.5 percent, and 2.5 percent.
HEALTHCARE
*CLIFFS: No premiums; no network changes; no changes to cost-sharing (such as copay,
deductibles, coinsurance, out-of-pocket maximums); eliminates requirement for spouse to elect
coverage.
*USS: No premiums, as long as USS agrees to the following: change its current PPO Medical
Plan network to the Blue High Performance Network, “which excludes many hospitals, doctors,
and physicians, and eliminates coverage of out-of-network provides (except in emergency)”;
eliminate coverage for high-cost specialty drugs obtained through a physician, clinic, or infusion
center, requiring all such specialty drugs to go through the Accredo Speciality Drug Program,
which decides whether a patient may self-administer or need additional tests; adopt SaveOn drug
program, “reducing plan reimbursement (increasing employee coinsurance) unless employee
enrolls and applies for copay assistance programs through drug manufacturers.”
BONUSES
*CLIFFS: No bonuses. “Instead, it’s reflected in wages that are with you forever and count
toward future earnings.”
*USS: $4,000 appreciation plus $3,000 ratification. “We told USS it can pay the $4,000 in a
signing bonus but we were not agreeing to this as written because USS did nothing for us during
the height of the pandemic, as requested by the union. USS should have appreciated us during
the heart of the pandemic, not when they’re trying to buy the contract.”
HOLIDAY
*CLIFFS: Add Juneteenth.
*USS: No response.
LEAVES OF ABSENCE
*CLIFFS: Two weeks parental leave; paid time off for victims of domestic abuse.
*USS: No response.
CAPITAL INVESTMENT
*CLIFFS: $4 billion.
*USS: $1 billion.
PENSION
*CLIFFS: Defined benefits—Effective 1/1/23, all years of service prior to 1/1/23 will have a
multiplier of $115; effective 1/1/23, all years of service going forward will have a multiplier of
$126. Steelworkers Pension Trust—effective 12/1/22, increase hourly contribution by $0.50.
*USS: No response.
RETIREE HEALTHCARE
*CLIFFS: Post 2016 hires, raise 401(K) contribution from $0.65 to $0.75.
*USS: No response.
PROFIT SHARING
*CLIFFS: Maintain at ArcelorMittal levels.
*USS: Unchanged.
SICKNESS AND ACCIDENT (S&A)
*Cliffs: Unchanged.
*USS: Eliminate automatic “recharge” of eligibility for S&A benefit after an employee returns to
work for 60 days, even if the second disability is unrelated to the prior one or is the result of a
difficult recovery or additional illness/injury.
“Your bargaining committee made it clear to USS that we deserve a fair contract that reflects our
sacrifices,” USW said. “We’ve worked very hard to achieve record profits that have greatly
benefited executives and shareholders. Their proposal needs to reflect our contribution. Keep up
the action. We need everyone’s support as we continue to push for what we deserve.
Vin
Vin
2023 had the big fintech write down.
The 1st quarter had a estimate of ($ 0.59) 3 months ago, ($ 0.61) 2 months ago and now is at ($ 0.75) . Wrong way
Biowatch
While trying to keep peace LG has given the USW everything. His contracts are all settled well in advance of their due date.
I believe his attitude is to spend whatever it is to keep everyone happy and then he expects the marketplace to pay the piper. Business doesn't work that way.
What if Nippon gets shunned and decides to enter the U,S, market through Southern Expansion? Good Night Irene
All I see is that LG is building a company that will never flourish in a competitive industry. He should hope that Nippon acquires US Steel so it is saddled by the obligations.
Didn't any of these guys read about the history of the steel industrials. The unions won everything until they didn't
I agree it's a non-cash charge but it does reduce the assets of the corporation similar to depreciation.. Cliffs also would benefit by reducing it's tax liability by a substantial sum,
13 new obesity drugs could hit the market by 2029 amid surging demand
https://seekingalpha.com/news/4091726-13-new-obesity-drugs-could-hit-the-market-by-2029-amid-surging-demand
vinny
Vinny
edcool and Vinny
The GLS system of testing comprises of 4 numbers. The numbers correspond to a word, not a scale.
0= NO Lines
1= Mild Lines
2= Moderate Lines
4= Severe Lines
So isn't measuring to MILD LINES Versus Moderate Lines A higher hill to climb?
Do your homework
Vin
And who's eyes beside the customer could define the difference between mild and moderate. What is acceptable.
Vin
After the fiasco with Revance I won't accept any beauty results from a clinical trial whereas the results are solely the decision of the patient. Revances #1 mistake was the promise of superiority.
If they promised little and delivered more they'd be king of the hill.
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
Business Wire
Wed, Apr 17, 2024, 4:05 PM EDT9 min read
In This Article:
EOLS
-3.40%
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS Annual Meeting
Data showed duration effect of 26 weeks, or 6 months, based on a ≥ 1-point Glabellar Line Scale (GLS) improvement and return to baseline value using the Global Aesthetic Improvement Scale
NEWPORT BEACH, Calif., April 17, 2024--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients.
The "extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra-Strength 40U and two active controls, BOTOX® 20U and Jeuveau® 20U.
Efficacy results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale. The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified.
"This publication provides the details of the study design along with the efficacy and safety data from the Phase 2 Jeuveau extra-strength study and makes it accessible to all," said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D of Evolus. "The study confirms the correlation between increasing dose and increasing duration, while maintaining a similar safety profile, with the majority of adverse events rated as mild."
With interest rates through the roof, congress diddling with the accelerated depreciation deductions and the questions surrounding the economy I'm seeing many mid sized companies sitting on their hands recently.
The big boys are buying, they just don't like paying.
Mondelez just submitted a contract stating that their current terms are that they will pay on the 3rd Friday of the month which will be no sooner than 210 Days after the invoice is accepted.
alertmeipp
Rvnc has to close to a bottom at this point. I would like to buy but after the whipping it gave me last year I won't touch it.
Revance will never become the company that we all hoped for but it can play in this field. It needs a new vision.
I've mentioned many times that their sales and management costs are completely out of whack while their therapeutic research is where the money should be spent..
Dismal
Could you please include the pronunciation in the future (tra-wus-fin-yiddy-who-gives-ah-rats-azz)
I think you're missing the point that CLF's bloodline is the government and someday that will change and they'll be in big trouble. Others in the industry are thriving while the Old boys will continue to disappear.
Nippons takeover of USS would be a huge bonus to the industry but it probably won't happen
I've been impressed with how LG turned the company around. I'm just not impressed with a industry that needs Government assistance to survive, The two things that saved Cliffs was first a President who loved tariff's and then a President who needs unions.at any cost.
I understand, so why would you show his timely purchases from that time period? Cliffs is only alive because President 1 loved Tariffs and President 2 loves the Unions.
I guess I have spellcheck spellcheck more often.
Mufaso,
With the lubricous pricing that Novo started with I also thought there will be the $1000 drug, maybe a $700 and maybe a $200 Drug. I've always claimed that the measuring stick of how much you can lose in xx weeks is absurd. Just put the people on a trendline as comfortably as possible.
Mufaso,
I'm taking everyone with a grain of salt until this gets sorted out.
Today Riley came out with this:
Altimmune has 'ideal lifestyle anti-obesity drug,' says B. Riley
B. Riley says Altimmune's Q4 earnings were headlined by two additional Phase II MOMENTUM obesity study findings, in follow-up to previously reported positive top-line data.
The new body composition sub-study data noted better quality of weight loss attained relative to more advanced weight loss drugs as only 25.5% of total weight loss was attributed to lean mass, which is comparable to normal diet-driven weight loss, the analyst tells investors in a research note.
In addition, new liver fat reduction data showed up to 79% subjects attained liver fat normalization, which reaffirms the "material de-risking" of the company's ongoing Phase II IMPACT 24-week liver biopsy metabolic dysfunction-associated steatohepatitis study readout anticipated in Q1 of 2025, says the firm. Riley believes the 25% lean mass reduction makes pemvidutide an "ideal lifestyle anti-obesity drug." It reiterates a Buy rating on Altimmune with a $20 price target.
Read more at:
https://thefly.com/n.php?id=3889181
WorstLuck
The key to me is that they're spending $1.47 in Q4 ($1.58 last year) for every $1.00 in sales after one year. So if the RHA is not growing it'll put more pressure on Daxi before we see any return.